Tirzepatide Improves Liver Biomarkers in Type 2 Diabetes Patients

What the researchers found

Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefits of GLP-1/GIP dual agonism alongside metabolic improvements.

Why it matters

Relevant to peptide therapeutics.

The numbers in context

16 patients enrolled, 13 completed 48 weeks. Tirzepatide started at 2.5 mg weekly with dose adjustments at physician discretion.

How the study worked

In publication.

Who was studied

Patients with MASLD and type 2 diabetes (16 enrolled, 13 completed 48 weeks)

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

• Long-term implications?
• Evidence comparison?
• Next steps?

Common questions

Read the original research

Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.

Hepatology research : the official journal of the Japan Society of Hepatology, 55(10), 1346-1352

Citation

Arai, Taeang; Atsukawa, Masanori; Nagao, Chikako; Yamada, Zento; Rokugo, Takahiro; Suzuki, Kenta; Kitamura, Michika; Higashi, Tetsuyuki; Koyano, Kaori; Hasegawa, Yuta; Kawano, Tadamichi; Ono, Hiroki; Yoshida, Yuji; Okubo, Tomomi; Hayama, Korenobu; Nakagawa-Iwashita, Ai; Itokawa, Norio; Kondo, Chisa; Nagao, Mototsugu; Iwabu, Masato; Iwakiri, Katsuhiko. (2025). Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.. Hepatology research : the official journal of the Japan Society of Hepatology, 55(10), 1346-1352. https://doi.org/10.1111/hepr.14241